HC Wainwright Has Negative View of ProKidney FY2030 Earnings

ProKidney Corp. (NASDAQ:PROK) – HC Wainwright dropped their FY2030 earnings per share estimates for ProKidney in a research report issued to clients and investors on Monday, May 18th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.10 per share for the year, down from their previous estimate of $0.17. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.72) per share.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.10 million.

Several other research firms have also recently weighed in on PROK. Wall Street Zen cut ProKidney from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a research report on Tuesday, April 21st. Finally, Jefferies Financial Group raised ProKidney to a “strong-buy” rating in a research report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

ProKidney Trading Down 3.0%

PROK stock opened at $1.61 on Tuesday. The stock’s fifty day simple moving average is $1.94 and its two-hundred day simple moving average is $2.17. ProKidney has a 1-year low of $0.54 and a 1-year high of $7.13. The stock has a market cap of $486.08 million, a P/E ratio of -3.04 and a beta of 1.70.

Hedge Funds Weigh In On ProKidney

Large investors have recently modified their holdings of the company. R Squared Ltd bought a new stake in ProKidney during the 1st quarter worth approximately $25,000. SummitTX Capital L.P. bought a new stake in ProKidney during the 1st quarter worth approximately $26,000. Cetera Investment Advisers bought a new stake in ProKidney during the 4th quarter worth approximately $28,000. AQR Capital Management LLC increased its holdings in ProKidney by 106.4% during the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after acquiring an additional 27,098 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in ProKidney during the 4th quarter worth approximately $65,000. 51.59% of the stock is currently owned by institutional investors.

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.